NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.38
  • Forecasted Upside: 136.05 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.42 (1.45%)

This chart shows the closing price for RCKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rocket Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCKT

Analyst Price Target is $69.38
▲ +136.05% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $69.38, with a high forecast of $100.00 and a low forecast of $43.00. The average price target represents a 136.05% upside from the last price of $29.39.

This chart shows the closing price for RCKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Rocket Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/19/2021SVB LeerinkReiterated RatingBuyHigh
9/7/2021Chardan CapitalReiterated RatingBuyMedium
8/19/2021SVB LeerinkReiterated RatingBuyHigh
8/10/2021Chardan CapitalReiterated RatingBuy$56.00Medium
8/10/2021Needham & Company LLCReiterated RatingBuy$75.00Medium
8/10/2021SVB LeerinkLower Price TargetOutperform$66.00 ➝ $62.00Medium
8/10/2021William BlairReiterated RatingBuyMedium
7/7/2021Chardan CapitalReiterated RatingBuyLow
4/1/2021SVB LeerinkBoost Price TargetOutperform$61.00 ➝ $66.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$64.00High
2/18/2021Needham & Company LLCInitiated CoverageBuy$75.00Medium
1/4/2021Piper SandlerBoost Price Target$60.00 ➝ $80.00N/A
12/15/2020UBS GroupInitiated CoverageBuy$75.00Medium
12/10/2020Evercore ISIBoost Price TargetOutperform$65.00 ➝ $100.00High
12/8/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $46.00High
12/8/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $50.00High
12/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/23/2020JPMorgan Chase & Co.Boost Price TargetOverweight$38.00 ➝ $43.00High
11/4/2020SVB LeerinkReiterated RatingOutperformMedium
10/16/2020Lifesci CapitalReiterated RatingOutperformLow
10/16/2020Chardan CapitalBoost Price TargetBuy$33.00 ➝ $35.00High
9/22/2020OppenheimerLower Price TargetOutperform$43.00 ➝ $33.00Low
8/9/2020CowenReiterated RatingBuyMedium
8/5/2020Ci CapitalReiterated RatingBuy$35.00High
7/13/2020OppenheimerReiterated RatingBuy$43.00High
7/13/2020Chardan CapitalReiterated RatingBuy$33.00High
7/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
6/1/2020OppenheimerInitiated CoverageBuyMedium
5/6/2020William BlairReiterated RatingBuyMedium
3/11/2020Chardan CapitalReiterated RatingBuy$33.00High
3/5/2020William BlairReiterated RatingBuyHigh
3/5/2020Chardan CapitalReiterated RatingBuy$33.00Low
12/9/2019OppenheimerBoost Price TargetOutperform$36.00 ➝ $42.00Low
12/6/2019Chardan CapitalReiterated RatingBuy$30.00Low
12/6/2019Robert W. BairdBoost Price TargetOutperform$30.00 ➝ $41.00High
11/17/2019CowenReiterated RatingBuyLow
11/7/2019CowenReiterated RatingBuyHigh
11/5/2019Chardan CapitalInitiated CoverageBuy$30.00High
9/26/2019Piper Jaffray CompaniesInitiated CoverageOverweightHigh
9/10/2019William BlairReiterated RatingBuyHigh
9/4/2019William BlairReiterated RatingBuyLow
8/22/2019William BlairReiterated RatingBuyLow
8/13/2019OppenheimerLower Price TargetOutperform$39.00 ➝ $37.00Medium
5/8/2019CowenReiterated RatingBuyLow
5/1/2019William BlairReiterated RatingBuyMedium
4/22/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
4/9/2019William BlairReiterated RatingBuyHigh
3/19/2019OppenheimerSet Price TargetBuy$39.00High
3/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$27.00High
3/5/2019OppenheimerSet Price TargetBuy$39.00High
2/26/2019CowenInitiated CoverageOutperformLow
2/5/2019CIBCInitiated CoverageOutperform ➝ Outperform$39.00Medium
2/5/2019OppenheimerInitiated CoverageOutperform$39.00 ➝ $39.00Low
11/27/2018SVB LeerinkInitiated CoverageOutperform$22.00High
11/27/2018William BlairReiterated RatingBuyHigh
11/7/2018William BlairReiterated RatingBuyHigh
10/18/2018William BlairReiterated RatingBuyMedium
9/13/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$30.00High
8/8/2018William BlairInitiated CoverageBuyMedium
7/10/2018William BlairInitiated CoverageOutperformHigh
5/11/2018CowenReiterated RatingBuyHigh
3/9/2018CowenInitiated CoverageOutperformMedium
1/30/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$27.00High
7/12/2017Canaccord GenuityDowngradeBuy ➝ HoldMedium
7/11/2017HC WainwrightDowngradeBuy ➝ Neutral$2.00High
6/26/2017Canaccord GenuitySet Price TargetBuy$3.00N/A
5/12/2017HC WainwrightReiterated RatingBuy$7.00Low
4/12/2017HC WainwrightReiterated RatingBuy$7.00High
3/17/2017HC WainwrightReiterated RatingBuy$7.00Low
3/16/2017Canaccord GenuitySet Price TargetBuy$3.00Medium
1/4/2017HC WainwrightReiterated RatingBuy$7.00N/A
1/3/2017Canaccord GenuitySet Price TargetBuy$9.00N/A
1/3/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$3.00N/A
12/20/2016Canaccord GenuitySet Price TargetBuy$20.00N/A
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/A
11/14/2016HC WainwrightReiterated RatingBuyN/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 31 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 31 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
  • 11 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Rocket Pharmaceuticals logo
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in New York, NY.
Read More

Today's Range

Now: $29.39
Low: $28.23
High: $29.50

50 Day Range

MA: $31.60
Low: $27.42
High: $36.58

52 Week Range

Now: $29.39
Low: $26.72
High: $67.48


203,128 shs

Average Volume

435,715 shs

Market Capitalization

$1.89 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Rocket Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rocket Pharmaceuticals in the last year: Chardan Capital, Evercore ISI, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for RCKT.

What is the current price target for Rocket Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Rocket Pharmaceuticals in the last year. Their average twelve-month price target is $69.38, suggesting a possible upside of 136.0%. Evercore ISI has the highest price target set, predicting RCKT will reach $100.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $43.00 for Rocket Pharmaceuticals in the next year.
View the latest price targets for RCKT.

What is the current consensus analyst rating for Rocket Pharmaceuticals?

Rocket Pharmaceuticals currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCKT will outperform the market and that investors should add to their positions of Rocket Pharmaceuticals.
View the latest ratings for RCKT.

What other companies compete with Rocket Pharmaceuticals?

How do I contact Rocket Pharmaceuticals' investor relations team?

Rocket Pharmaceuticals' physical mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company's listed phone number is (646) 440-9100 and its investor relations email address is [email protected] The official website for Rocket Pharmaceuticals is